Alaunos Therapeutics, Inc.
TCRT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001107421
No open-market purchases or sales by Alaunos Therapeutics, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $204.4K in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $4.14M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +2 vs. previous quarter
- 29
- 13F valueReported value at the end of Q2 2026
- $204.4K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $5.00K
- −50.0% year over year
- Net income, FY2025
- -$4.18M
- No comparable prior period
- Free cash flow, FY2025
- -$2.97M
- No comparable prior period
- Revenue, Q2 FY2026
- $0
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $4.18M (83520.0% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 184.4K
- Shares sold short
- Change
- −634.2K
- −77.5% vs. previous
- Days to cover
- 1.00
- At average daily volume
Superinvestors holding TCRT, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding TCRT at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Alaunos Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 26, 2025 (view filing) | Jun 24 | 2 days | Vieser JaimeDirector | PPurchase | +55.7K | $0.0202 | +$1.12K | –250 after | Derivative |
| Jun 26, 2025 (view filing) | Apr 11-Jun 24 | 76 daysLate | Postma Robert WDirector | PPurchase | +314.8K | $0.0129 | +$4.07K | –600 after | Derivative2 lots |
| Apr 15, 2025 (view filing) | Apr 11 | 4 days | Postma Robert WDirector | PPurchase | +181.2K | $0.0076 | +$1.38K | –500 after | Derivative |
| Jan 3, 2025 (view filing) | Dec 31, 2024 | 3 days | Vieser JaimeDirector | SSale | −3.00K | $2.01 | −$6.02K | −10.4%25.9K after | 2 lots |
| Sep 5, 2023 (view filing)5:34 PM ET | Sep 1 | 4 days | Boyle Kevin S. Sr.Chief Executive Officer | SSale | −68.0K | $0.1403 | −$9.54K | −7.9%798.2K after | 10b5-1 |
| Dec 1, 2022 (view filing) | Nov 29 | 2 days | Postma Robert WDirector | PPurchase | +750.0K | $0.65 | +$487.5K | +17.6%5.00M after | |
| Dec 1, 2022 (view filing) | Nov 29 | 2 days | Vieser JaimeDirector | PPurchase | +1.25M | $0.65 | +$812.5K | New position1.25M after | |
| Dec 27, 2021 (view filing) | Dec 22 | 5 days | De Groot EleanorEVP, Operations | SSale | −20.1K | $1.27 | −$25.6K | −7.8%237.1K after | |
| Nov 17, 2021 (view filing) | Nov 16-17 | 1 day | Boyle Kevin S. Sr.Chief Executive Officer | PPurchase | +10.0K | $1.40 | +$14.0K | +1.1%885.0K after | 2 lots |
| Oct 4, 2021 (view filing) | Sep 29 | 5 daysLate | Vieser JaimeDirector | PPurchase | +100.0K | $1.91 | +$191.0K | +16.5%705.3K after |
Top 10 13F holders, Q2 2026
See all 29 holdersThe largest institutional positions in Alaunos Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 21,353 | $48.3K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 19,356 | $43.8K | 0.00% | −3,204−14.2% | Reduced |
| Vanguard Fiduciary Trust Co | 15,497 | $35.0K | 0.00% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 14,063 | $31.8K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 11,870 | $26.8K | 0.00% | +1,351+12.8% | Added |
| Advisor Group Holdings, Inc. | 1,731 | $3.91K | 0.00% | −48−2.7% | Reduced |
| Tower Research Capital LLC (TRC) | 1,621 | $3.66K | 0.00% | +38+2.4% | Added |
| SRS Capital Advisors, Inc. | 1,216 | $2.75K | 0.00% | +1,216 | New |
| UBS Group AG | 992 | $2.24K | 0.00% | −1,282−56.4% | Reduced |
| Morgan Stanley | 836 | $1.89K | 0.00% | +183+28.0% | Added |
Holders of 5% or more of TCRT
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Alaunos Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 13D | 19.99%858.8K shares | New | Oct 15, 20261 filing | Oct 15, 2026 | SEC |
| Postma Robert W | 13D/A | 9.99%514.7K shares | +0.99 ppfrom 9.00% | Jul 1, 20252 filings | Oct 15, 2026 | SEC |
| Price Adrian | 13D/A | 8.60%189.1K shares | 0.00 ppfrom 8.60% | Oct 30, 20255 filings | Mar 5, 2026 | SEC |